Treating polyarteritis nodosa: current state of the art

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Polyarteritis nodosa (PAN) treatment guidelines are complex due to evolving definitions and overlapping classifications with other vasculitides.
• Clinical trials often included mixed patient populations, complicating specific treatment recommendations for PAN.

Purpose of the Study:

• To review current evidence and expert recommendations for managing polyarteritis nodosa (PAN).
• To outline severity-adapted treatment strategies for idiopathic generalized PAN.
• To discuss management approaches for hepatitis B virus-associated PAN and cutaneous PAN.

Main Methods:

• Review of clinical trial data for PAN and related vasculitides.
• Analysis of uncontrolled studies on hepatitis B virus-associated PAN.
• Summary of expert recommendations for cutaneous PAN treatment.

Main Results:

• Idiopathic generalized PAN benefits from a severity-adapted approach: high-dose glucocorticoids and cyclophosphamide for severe cases, glucocorticoids alone for non-severe cases.
• Hepatitis B virus-associated PAN management involves antiviral agents, short-term glucocorticoids, and plasma exchange.
• Limited evidence exists for cutaneous PAN, with expert recommendations favoring less aggressive therapies like NSAIDs, colchicine, or dapsone.

Conclusions:

• A severity-adapted strategy is supported for idiopathic generalized PAN.
• Specific management protocols exist for hepatitis B virus-associated PAN.
• Further research is needed to establish robust evidence-based guidelines for all PAN variants, especially cutaneous PAN.